Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01904734 · ClinicalTrials.gov registry record · Phase 2

Clomid in Men With Low Testosterone With and Without Prior Treatment

A Phase 2 study of Hypogonadism, Male, sponsored by Phoenix VA Health Care System.

Completed
Registry status
Phase 2
Development phase
42
Enrollment target
1
Study location

NCT01904734: Completed Phase 2 study of Hypogonadism, Male, sponsored by Phoenix VA Health Care System.

NCT01904734 is a Phase 2 study of Hypogonadism, Male that has completed, run by Phoenix VA Health Care System. The registered enrollment target is 42 participants, below the 109-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01904734, a Phase 2 study of Hypogonadism, Male, has completed, sponsored by Phoenix VA Health Care System.

COMPLETED
Registry status
Phase 2
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility that has been shown to improve male hormone secretion in some cases.

Primary Outcome

laboratory measurement by standard immunometric method

Conditions Studied

Interventions

  • DRUG Clomiphene

Study Locations (1)

Arizona

  • Phoenix VA Health Care System - Phoenix

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2012-10
Est. Completion 2018-10-31
Phase Phase 2
Phoenix VA Health Care System

7 total trials

What the finished NCT01904734 record still lists

NCT01904734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 109-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Clomiphene is the first listed.

NCT01904734 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT01904734 about?

NCT01904734 is a clinical study titled "Clomid in Men With Low Testosterone With and Without Prior Treatment". This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility ...

What is the current status of trial NCT01904734?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-10. Estimated completion is 2018-10-31.

What conditions does trial NCT01904734 study?

This clinical trial studies the following conditions: Hypogonadism, Male.

What interventions are being tested in trial NCT01904734?

The interventions under investigation include: Clomiphene (DRUG).

Who is sponsoring clinical trial NCT01904734?

This trial is sponsored by Phoenix VA Health Care System, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01904734 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypogonadism, Male

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01904734's enrollment target sits among peer trials

42 11th of 12 higher than 2 of 12 other Hypogonadism, Male trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypogonadism, Male trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01904734, the US trial registry maintained by the National Library of Medicine. NCT01904734 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.